Project description:To identify functional targets of miR-340, we compared the gene expression profiles of miR-340 overexpressing human GICs with the profiles of their parental cells. The precursor form of miR-340 or control miRNA was overexpressed in glioma cells using miRNA lentiviral particles. The cells were incubated with recombinant virus at 37°C for 12 hr and cultured in the presence of puromycin for 3 days.
Project description:To identify functional targets of miR-340, we compared the gene expression profiles of miR-340 overexpressing human GICs with the profiles of their parental cells.
Project description:To identify a novel miRNA that is aberrantly expressed in GICs, we analyzed differences in miRNA expression between the mouse GICs, NSCL61 and OPCL61, showing characteristic features of cancer stem cell, and their parental cells by miRNA microarrays. neural stem cells, glioma-initiating cells (GICs) from neural stem cells, oligodendrocyte precursor cells, glioma-initiating cells (GICs) from oligodendrocyte precursor cells.
Project description:To find factors and pathways that Eva1 regulates in NSCL61 We identified Eva1 as a new factor expressed in glioma-initiating cells (GICs). Eva1 regulates the proliferation of GICs.
Project description:Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults, with glioma initiating cells (GICs) implicated to be critical for tumor progression and resistance to therapy. The hypoxic tumor microenvironment has been shown to play an important role to maintain the GICs; however, the mechanisms regulating responses of GICs to hypoxia remain poorly understood.
Project description:To identify factors involved in tumorigenicity of glioma-initiating cells (GICs), we compared gene expression in GIC-like cells with and without sox11 expression. We established sox11-expressing mouse glioma-initiating cell (GIC)-like cell line (NSCL61s), NSCL61s-sox11, which lost tumorigenicity when transplanted in vivo. We think that genes, which are differently expressed between NSCL61s and NSCL61s-sox11, would be new targets for glioma therapy.
